An international one year TEMPO trial reports in addition to the usual methotrexate therapy, rheumatoid arthritis patients also benefits from ENBREL* (etanercept), a biological treatment. A report ...
Amsterdam – Rheumatoid arthritis patients who are on standard methotrexate therapy may benefit from the addition of the biologic treatment, ENBREL* (etanercept), according to new data from a one-year, ...
LOS ANGELES, Nov 7 (Reuters) - Early results from an ongoing study showed that people with newly diagnosed rheumatoid arthritis were more likely to reach clinical remission with Amgen Inc and Wyeth's ...
Amgen and marketing partner Wyeth have been boosted by interim data from a study which shows that a combination of Enbrel and methotrexate is highly effective as a treatment for active early ...
The goals of RA treatment can be achieved within a year of combined therapy with Wyeth’s Enbrel and the standard methotrexate in patients with severe disease who are treated early and these effects ...
A new study published online by The Lancet on July 15, 2008, said that most patients taking a combination of Enbrel and methotrexate had no progression of joint damage halfway into a two-year study.
ENBREL can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. ENBREL is also indicated in the treatment of severe, active ...
Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- ...
-- Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel(R) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps ...
With Pfizer poised to hand off full promotional responsibilities for Enbrel to its partner Amgen, New England Journal of Medicine has published a study suggesting that the $4 billion RA drug may not ...
SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback